Early Phase Clinical Research Support. Definitive testing of the value of novel therapeutics and diagnostics in large randomized trials requires the prior execution of "early phase" trials that provide the information needed to design pivotal studies. Phase 1 trials are directed at determining doses of drug that are appropriate for subsequent trials and the pattern of adverse events produced. Feasibility and pilot trials are conducted to obtain preliminary information on the tolerability of particular drug combinations, the ability to measure effects on drug targets, or to assess whether a particular biomarker or imaging technology can assist in predicting or assessing response. Our emphasis has been on innovative technology discovered in MCC labs as well as translating basic biological discoveries in MCC labs into clinical trials that benefit patients. In calendar year 2012, 145 patients accrued to 48 interventional treatment studies in Early Phase Therapeutics. An emphasis on genomic profiling and targeted therapy is now emerging, and will be fundamental to future trials. In the future, there will be a focus on and significant expansion of the development and clinical testing of new agents, matching agents with patients based on molecular profile, bringing drugs discovered at MCC into phase I testing, and expansion of the depth and breadth of academic and industry partnerships.
The availability of Early Phase Clinical Research enables our researchers to transition discoveries from UCSD Moores Cancer Center basic science laboratories to human clinical trials. This is critical to the successful development and regulatory approval of new cancer treatments and diagnostic tools.
|Akers, Johnny C; Ramakrishnan, Valya; Yang, Isaac et al. (2016) Optimizing preservation of extracellular vesicular miRNAs derived from clinical cerebrospinal fluid. Cancer Biomark 17:125-32|
|Hoffmann, Hanne M; Trang, Crystal; Gong, Ping et al. (2016) Deletion of Vax1 from Gonadotropin-Releasing Hormone (GnRH) Neurons Abolishes GnRH Expression and Leads to Hypogonadism and Infertility. J Neurosci 36:3506-18|
|Baumgartner, Joel M; Kwong, Thomas G; Ma, Grace L et al. (2016) A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 23:1609-17|
|Meyskens Jr, Frank L; Mukhtar, Hasan; Rock, Cheryl L et al. (2016) Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst 108:|
|Hussain, Timon; Savariar, Elamprakash N; Diaz-Perez, Julio A et al. (2016) Surgical molecular navigation with ratiometric activatable cell penetrating peptide for intraoperative identification and resection of small salivary gland cancers. Head Neck 38:715-23|
|Singh, Alok R; Joshi, Shweta; Zulcic, Muamera et al. (2016) PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS One 11:e0150836|
|Liu, Lin; Messer, Karen; Baron, John A et al. (2016) A prognostic model for advanced colorectal neoplasia recurrence. Cancer Causes Control 27:1175-85|
|Nuyen, Brian A; Fox, Rina S; Malcarne, Vanessa L et al. (2016) Excessive Daytime Sleepiness as an Indicator of Depression in Hispanic Americans. Hisp Health Care Int 14:116-23|
|Ghosh, Pradipta; Aznar, Nicolas; Swanson, Lee et al. (2016) Biochemical, Biophysical and Cellular Techniques to Study the Guanine Nucleotide Exchange Factor, GIV/Girdin. Curr Protoc Chem Biol 8:265-298|
|Johns, Claire; Seav, Susan M; Dominick, Sally A et al. (2016) Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Res Treat 156:415-26|
Showing the most recent 10 out of 699 publications